<u>**Supplemental TOC**</u>
**Table 1S. Categorical exposure variables based on years of exposure to NSAIDs**
**Table 2S. eGFR change over 12 months among NSAID unexposed and exposed patients taking ACEi/ARB or diuretics**

Table 1S. Categorical exposure variables based on years of exposure to NSAIDs

| Categorical exposure variable | N | Total exposure Min, Max (months) | Average number of NSAIDs Mean (sd) | Average total exposure Mean (sd) |
|---|---|---|---|---|
| 0 | 52,024 | 0 | 0 | 0 |
| 1 | 15,021 | >0 to 24 | 1.06 (.26) | 19.0 (7.7) |
| 2 | 18,355 | >24 to 48 | 1.19 (.43) | 44.9 (6.2) |
| 3 | 1,175 | >48 to 60 | 2.29 (.48) | 53.8 (3.7) |
| 4 | 11,124 | >60 | 2.51 (.70) | 94.4 (26.9) |

Table 2S. eGFR change over 12 months among NSAID unexposed and exposed patients taking ACEi/ARB or diuretics

| eGFR over time | N=97,232 | |
|---|---|---|
| Variable | Adjusted models Coefficient (SE) | p-value |
| Intercept (by propensity score quintile) | 92.35 (.18) | ---- |
| Age | -.2450 (.0036) | <.0001 |
| Gender<br>    Female<br>     Male (ref) | -.0723 (.0581) | .2136 |
| Diabetes | -.1591 (.1382) | .2495 |
| Heart Failure | .1915 (.3351) | .5676 |
| HTN | .0561 (.0680) | .4094 |
| Liver disease | .1642 (.2070) | .4278 |
| Obesity | .1297 (.1324) | .3274 |
| ACEi/ARB | .4358 (.1695) | .0101 |
| Diuretic | -.6263 (.1478) | <.0001 |
| CKD Stage 3 | -22.6818 (.0756) | <.0001 |
| NSAID dose (at baseline) | .1551 (.0240) | <.0001 |
| eGFR change per 12 months in non-exposed (slope) | -.1332 (.0198) | <.0001 |
| Difference in eGFR slope for NSAID exposed patients taking concomitant ACEi/ARB | -.1379 (.0774) | .0750 |
| Difference in eGFR slope for NSAID exposed patients taking concomitant diuretics | -.1464 (.0663) | .0272 |
| *Difference* in eGFR slope per dose unit increase for all NSAID exposed patients | *-.0639 (.0108)* | *<.0001* |